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http://dx.doi.org/10.1016/j.ccell.2017.03.007SUMMARYAberrant WNT signaling drives colorectal cancer (CRC). Here, we identify TIAM1 as a critical antagonist of
CRC progression through inhibiting TAZ and YAP, effectors of WNT signaling. We demonstrate that TIAM1
shuttles between the cytoplasm and nucleus antagonizing TAZ/YAP by distinct mechanisms in the two
compartments. In the cytoplasm, TIAM1 localizes to the destruction complex and promotes TAZ degradation
by enhancing its interaction with bTrCP. Nuclear TIAM1 suppresses TAZ/YAP interaction with TEADs,
inhibiting expression of TAZ/YAP target genes implicated in epithelial-mesenchymal transition, cell migra-
tion, and invasion, and consequently suppresses CRC cell migration and invasion. Importantly, high nuclear
TIAM1 in clinical specimens associates with increased CRC patient survival. Together, our findings suggest
that in CRC TIAM1 suppresses tumor progression by regulating YAP/TAZ activity.INTRODUCTION
Intestinal epithelial cells transform into malignant cells following
mutations in various oncogenes and tumor suppressors that
drive changes in programsof gene expression. Typically, the initi-
ating event is inactivation of the tumor suppressor adenomatous
polyposis coli (APC) or, less frequently, activation of b-catenin,
resulting in constitutive activation of the canonicalWNTpathway.
At the core of this pathway is the regulation ofb-catenin by a cyto-Significance
Colorectal carcinogenesis typically commences with constitu
scriptional co-activators including TAZ and YAP. Thereafter,
program that propels invasion and metastasis. We herein ide
complex regulating TAZ/YAP stability. We further show that w
complex is inactivated, TIAM1 along with TAZ/YAP accumulat
nucleus, however, TIAM1 continues to antagonize nuclear T
thereby suppresses cell migration and invasion. In keeping
advanced colorectal cancer, and low nuclear TIAM1 predicts
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This is an open access article undplasmic destruction complex. In the absence of a WNT signal,
the central scaffold protein AXIN within the destruction complex
binds APC which efficiently delivers cytosolic b-catenin to be
phosphorylated by CK1 and then GSK3b. Phosphorylated b-cat-
enin is subsequently ubiquitylated by the E3 ligase bTrCP and
degraded by the proteasome. Binding of WNT to its receptor
causes inactivation of the destruction complex, stabilization,
and nuclear translocation of b-catenin, and subsequent tran-
scription by a b-catenin/TCF complex (Clevers, 2006).tive WNT signaling leading to nuclear accumulation of tran-
mutational and epigenetic events ensue inducing a genetic
ntify TIAM1 as a component of the cytoplasmic destruction
hen, as in initiated intestinal epithelial cells, the destruction
e and translocate from the cytoplasm to the nucleus. In the
AZ/YAP function despite constitutive WNT signaling, and
with these findings, nuclear TIAM1 is downregulated in
poor prognosis.
, May 8, 2017 ª 2017 The Author(s). Published by Elsevier Inc. 621
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
The transcriptional co-activators TAZ and YAP (TAZ/YAP;
originally identified as targets of the HIPPO pathway) have
recently been established as additional regulatory components
but also as effectors of canonical WNT signaling. In the cyto-
plasm, TAZ/YAP interact with b-catenin directly and restrict
b-catenin nuclear translocation (Imajo et al., 2012). Cytoplasmic
TAZ/YAP also interact with DVL, a regulator of the destruction
complex, inhibiting DVL phosphorylation by CK1 and conse-
quently inhibiting b-catenin activation (Varelas et al., 2010). A
further study showed that in the absence of WNT, TAZ/YAP
are essential for bTrCP recruitment to the destruction complex
and b-catenin degradation (Azzolin et al., 2014). Thus, cyto-
plasmic TAZ/YAP emerge as inhibitors of WNT signaling and,
therefore, potential suppressors of colorectal cancer (CRC).
Inactivation of the destruction complex, either through WNT
stimulation or, as occurs in CRC cells, inactivation of APC, re-
sults in not only b-catenin but also TAZ/YAP stabilization and
the opportunity for TAZ/YAP to translocate to the nucleus (Azzo-
lin et al., 2012, 2014). Significantly, in contrast to the ability of
TAZ/YAP to downregulate b-catenin in the cytoplasm, nuclear
YAP seems to cooperate with b-catenin to transactivate WNT
target genes (Azzolin et al., 2012; Rosenbluh et al., 2012). TAZ/
YAP stimulate target gene expression involved in cell prolifera-
tion, stem cell self-renewal, and tumorigenesis through binding
TEAD family transcription factors in the nucleus (Zhang et al.,
2009; Zhao et al., 2008). In keeping, TAZ/YAP are required for
the overgrowth of intestinal crypts and formation of adenomas
following APC inactivation (Azzolin et al., 2014; Gregorieff
et al., 2015) and TAZ/YAP expression is associated with poor
prognosis of CRC patients (Wang et al., 2013; Yuen et al.,
2013). Thus, the interaction between TAZ/YAP and the WNT
pathway is complex, highlighting our incomplete understanding
of how the pathway is regulated. In the present study, we inves-
tigated the role of TIAM1, a guanine nucleotide exchange factor
specific for RAC1, in colon cancer progression.
RESULTS
Nuclear TIAM1 Expression in Human Tumors is a
Prognostic Marker for CRC Progression
Previously, using recombinant mouse models, we have shown
that TIAM1 cooperates with WNT signaling during initiation of
intestinal epithelial neoplasia but then appeared to antagonize
tumor progression (Malliri et al., 2006). However, howTIAM1 influ-
ences intestinal tumor initiationandprogression remainedelusive.
To further address the impact of TIAM1on intestinal neoplasia and
increase our understanding of its clinical significance, we probed
a tissue microarray (TMA) comprising 650 samples, including
Dukes stages A to C, from a well-characterized patient cohort
(Brown et al., 2014) (Table S1), with a pre-validated TIAM1 anti-
body (Marei et al., 2016; Vaughan et al., 2015; Whalley et al.,
2015). Intriguingly, we detected TIAM1 not only in the cytoplasm
but also in cell nuclei (Figure 1A). Furthermore, nuclear TIAM1
staining intensity decreased with advancing Dukes stage (c2 =
54.165, p < 0.001) (Figures 1A, 1B, and S1A). TIAM1 cytoplasmic
staining alsodecreasedwith advancingDukes stage (c2 = 19.057,
p = 0.001) (Figures 1A and S1B). Thus, TIAM1 expression is nega-
tively associated with colon cancer progression, consistent with
our previous finding that TIAM1 antagonized progression of intes-622 Cancer Cell 31, 621–634, May 8, 2017tinal tumors inApcMin/+mice (Malliri et al., 2006). To determine the
association between TIAM1 expression and overall survival, we
grouped nuclear TIAM1 staining into low (scores 0–1) or high
(scores 2–3) categories and found that patients having CRC with
high nuclear TIAM1 had significantly better survival than patients
having CRC with low nuclear TIAM1 (Figures 1C and S1C). How-
ever, no difference was found in overall survival between patients
having CRC expressing low or high cytoplasmic TIAM1 (Fig-
ure S1D). Thus, high levels of nuclear TIAM1 could serve as a
good prognostic factor for CRC patients.
TIAM1 Nucleocytoplasmic Shuttling is Regulated by a
Functional Nuclear Localization Signal
To validate TIAM1 nuclear localization, we analyzed its expres-
sion in CaCo2, DLD1, and SW620 CRC cell lines. TIAM1 was de-
tected predominantly in nuclei from all three cell lines (Figure 2A).
Furthermore, depletion of TIAM1 using two different small inter-
fering RNAs (siRNAs) reported previously (Vaughan et al., 2015;
Whalley et al., 2015) dramatically reduced the nuclear signal in all
three lines (Figure 2A), verifying the specificity of the staining.
Specificity of the nuclear TIAM1 staining was also verified in
two independent clones of SW480 cells with TIAM1 ablated
using CRISPR (Figures S2A–S2C).
We next addressed the mechanism of TIAM1 recruitment to
the nucleus. Nuclear entry of proteins as large as TIAM1 that
are unable to diffuse passively through nuclear pores is selec-
tive, dependent on the presence of a nuclear localization signal
(NLS) (Freitas and Cunha, 2009). We therefore examined
whether TIAM1 has a functional NLS. In silico analysis revealed
two putative bipartite NLSs, but no monopartite NLS (Fig-
ure S2D). Between the two putative NLSs, the second had a
high confidence score of 9.4 (Figure S2D), and aligning peptide
sequences from different species revealed that NLS2 was more
highly conserved (Figure S2E), implying an important regulatory
function.
To investigate the functionality of the putative NLSs, we gener-
ated GFP-tagged TIAM1 constructs with the predicted NLSs
deleted. The TIAM1DNLS1 construct contained a deletion in
amino acids 269–298 and the TIAM1DNLS2 construct in amino
acids 684–710. The constructs were transiently overexpressed
in the DLD1 cell line and the number of cells with nuclear
or non-nuclear localization defined by confocal microscopy.
As expected, exogenously expressed full-length TIAM1 (FL-
TIAM1-GFP) was detected both in the nucleus and the cyto-
plasm (Figure S2F), as was TIAM1-DNLS1 (data not shown);
however, we observed significantly less TIAM1-DNLS2 in nuclei
(Figure S2F). To further interrogate the role of NLS2 in controlling
nuclear localization of TIAM1, we generated three different
GFP-tagged TIAM1 mutants in which the clusters of basic resi-
dues 688KRR690 and 704KKK706 weremutated to AAA (Figure 2B).
Cells expressing any of the three mutations in NLS2 displayed a
significant decrease in nuclear TIAM1 (Figure 2C). Our results
indicate, therefore, that TIAM1 shuttles between the cytoplasm
and the nucleus mediated by at least one functional NLS.
TIAM1 Antagonizes Transcription of TAZ/YAP
Target Genes
The nuclear localization of TIAM1 suggested a possible role in
regulating gene expression, whose interrogation might allow us
Figure 1. Abundance of Nuclear TIAM1 Impacts on CRC Progression
(A) Immunohistochemical analysis of TIAM1 expression in a tissue microarray (TMA) of human colorectal cancers showing representative examples of strong
(score 3), moderate (score 2), weak (score 1), and negative (score 0) staining. Scale bars, 100 mm.
(B) Quantitation of TIAM1 nuclear staining intensity in CRC patients diagnosed with Dukes A, Dukes B, and Dukes C stage (c2 = 54.165, p < 0.001).
(C) Cumulative overall survival for patients with high (moderate/strong) and low (weak/negative) TIAM1-expressing tumors. HR, hazard ratio; CI, confidence
interval.
See also Figure S1 and Table S1.to elucidate the contribution of TIAM1 to CRC development. By
performing RNA sequencing (RNA-seq) on SW620 cells trans-
fected with either siTIAM1#1 or a negative control siRNA (siNT)
(Figure S3A), we identified TIAM1 differentially expressed genes
(Table S2). The expression profiles of siNT and siTIAM1#1 sam-
ples were clearly separated based on principal component anal-
ysis (Figure S3B), and 5,027 genes were found to be differentially
expressed (false discovery rate <0.05) between the two popu-
lations (Figure 3A). To surmise molecular pathways associated
with TIAM1 regulated genes, we performed gene set enrichment
analysis (GSEA) using gene sets for the oncogenic pathways
in the Molecular Signature Database (MSigDB) (Subramanian
et al., 2005). GSEA revealed significant enrichment among
TIAM1-regulated genes for apical polarity and epithelial-mesen-
chymal transition (EMT) signatures (Figure 3B), cellular pro-
cesses well known to be regulated by TIAM1 (Mack et al.,
2012; Vaughan et al., 2015;Woodcock et al., 2009). Interestingly,
we also found that TIAM1-regulated genes overlapped signifi-
cantly with the YAP-associated molecular signature (Cordenonsiet al., 2011) (Figure 3B). Indeed, numerous well-characterized
TAZ/YAP target genes were found to be upregulated in
the RNA-seq dataset upon knockdown of TIAM1 (Figure 3C).
Furthermore, five target genes (AMOTL2, ANKRD1, AXL,
CTGF, and CYR61) were validated to be upregulated by qRT-
PCR in both SW620 and SW480 cells using two independent
siRNA sequences targeting TIAM1 (Figures 3D, S3C, and S3D).
These findings indicated that TIAM1 might be antagonizing
induction of TAZ/YAP target genes.
Given the important role of TAZ/YAP in CRC, we decided to
investigate further the interplay of TIAM1 with TAZ/YAP. First,
we tested whether the effect of TIAM1 depletion on the expres-
sion of CTGF and CYR61 was also observed in vivo. As shown in
Figure 3E, the levels of both CTGF and CYR61 were upregulated
in the small intestines of Vil-Cre-ERT2 Apcfl/fl Tiam1/ compared
with Vil-Cre-ERT2 Apcfl/fl mice treated with tamoxifen. Second,
using RNA-seq we generated a list of TAZ/YAP differentially ex-
pressed genes from SW620 cells transfected with either specific
siRNAs for TAZ/YAP or a negative control siRNA (Figure S3E andCancer Cell 31, 621–634, May 8, 2017 623
Figure 2. TIAM1 Nucleocytoplasmic Shut-
tling is Regulated by a Bipartite NLS
(A) Representative confocal images of TIAM1
localization in three different CRC cell lines
carrying APC mutations. TIAM1-depleted cells
(TIAM1 siRNA) are used to demonstrate TIAM1
staining specificity. Scale bars, 10 mm.
(B) Schematic representation of the position and
sequence of the NLS of TIAM1 and the NLS
mutants employed to study TIAM1 nucleocyto-
plasmic shuttling.
(C) Representative confocal images of DLD1
cells transiently transfected with GFP-tagged
FL-TIAM1 and the three different TIAM1-NLS
mutants. Scale bars, 10 mm. Graph shows
quantitation from three independent experiments
(n = 50 cells per experiment). Data are presented
as mean ± SEM, unpaired t test: **p < 0.01,
***p < 0.001.
See also Figure S2.Table S3) and compared it with the siTIAM1#1 RNA-seq dataset.
Interestingly, we found that 50% of TAZ/YAP-regulated genes
were also TIAM1 dependent (Figure 3F).
TIAM1 Regulates TAZ Stability and Nuclear
Translocation
The inverse association between TAZ/YAP and TIAM1-regulated
genes prompted us to investigate the molecular mechanism(s)
by which TIAM1 might antagonize TAZ/YAP. Depletion of
TIAM1 in HEK293 cells (Figure S4A) using siTIAM1#1 resulted
in a statistically significant increase of TAZ protein both in the
cytoplasm and in the nuclei of HEK293 cells comparable with
that induced by APC depletion (Figure 4A). A similar effect on
TAZ was observed after depletion of TIAM1 by a second siRNA
sequence (siTIAM1#2) (Figure S4B). Because TAZ mRNA levels
were not significantly upregulated by TIAM1 depletion (Fig-
ure S4C), this suggested that TIAM1 depletion promoted the
stabilization and nuclear translocation of TAZ. YAP stability,
and nuclear translocation also appeared to increase upon
TIAM1 and APC depletion (Figures 4A and S4B).
To further investigate the relationship between TIAM1 and
TAZ/YAP, we tested the effect of TIAM1 depletion on the activ-624 Cancer Cell 31, 621–634, May 8, 2017ity of 8xGTIIC-Lux, a synthetic lucif-
erase reporter containing multimerized
response elements of TEAD, the main
DNA-binding cofactor of TAZ or YAP
(Dupont et al., 2011). As shown in
Figure 4B, TIAM1 depletion strongly
induced the activity of 8xGTIIC-Lux, indi-
cating that TIAM1 regulates TAZ/YAP
activity. Depletion of endogenous TAZ
alone partially rescued the effect of
TIAM1 depletion (Figures S4D and
S4E), while depletion of YAP or a combi-
nation of YAP and TAZ was even more
effective at reversing the effect (Figures
4B, S4D, and S4E). Moreover, the
expression of the endogenous TAZ/YAP target genes CTGF and CYR61 was also shown to be up-
regulated by TIAM1 depletion in both HEK293 and HaCaT cells
(Figures 4C and S4E–S4G). Again this effect could be reversed
by depleting TAZ or YAP alone, and particularly through com-
bined depletion of both (Figures 4C and S4E–S4G). Analysis
of target gene expression and activity of a synthetic reporter
thus confirmed the ability of TIAM1 to antagonize the function
of both TAZ and YAP.
Finally, we decided to investigate the mechanism by which
TIAM1 depletion induced the stability of TAZ. As previous
studies have shown that the E3 ubiquitin ligase bTrCP interacts
directly with both TAZ (Azzolin et al., 2012; Huang et al., 2012;
Liu et al., 2010) and TIAM1 (Magliozzi et al., 2014; Zhu et al.,
2014), we hypothesized that TIAM1 might regulate the interac-
tion of TAZ with bTrCP. By carrying out immunoprecipitations
for endogenous bTrCP from confluent control or TIAM1-
depleted HEK293 cells, we found that the interaction of TAZ
with bTrCP was decreased in cells in which TIAM1 expression
was downregulated (Figure 4D). Taken together, these results
indicate that TIAM1 is important for the interaction of TAZ with
bTrCP through which it regulates the stability and cellular distri-
bution of TAZ.
Figure 3. TIAM1 Suppresses a TAZ/YAP Transcriptional Program
(A) Heatmap depiction of differentially expressed genes between siNT and siTIAM1#1 transfected SW620 cells from three independent experiments. A total of
2,487 genes (in red) are positively correlated with TIAM1 depletion and 2,541 genes (in blue) are negatively correlated.
(B) GSEA with a significant enrichment score showing biological processes and signaling pathways that are positively correlated with TIAM1 knockdown in
SW620 cells. FDR, false discovery rate; NES, normalized enrichment score.
(C) Heatmap depiction of all differentially expressed genes between siNT and siTIAM1#1 transfected SW620 cells that contribute to the YAP conserved signature.
(D) qPCR for TAZ/YAP target genes AMOTL2, ANKRD1, AXL, CTGF, and CYR61 normalized to ACTB expression in SW620 and SW480 cells transfected with
TIAM1#1 siRNA. Data are relative to negative control siRNA (siNT; set as 1) and are presented as mean ± SEM (unpaired t test: *p < 0.05, **p < 0.01, ***p < 0.001).
(E) Representative images of immunohistochemistry for CTGF and CYR61 in Vil-Cre-ERT2 Apcfl/fl and Vil-Cre-ERT2 Apcfl/fl Tiam1/ intestines of tamoxifen-
treated mice. Scale bars, 100 mm.
(F) Venn diagram showing overlap of TIAM1 and TAZ/YAP target genes as determined by RNA-seq analysis (differentially expressed genes between siNT and
siTAZ/YAP transfected SW620 cells were determined from three independent experiments).
See also Figure S3; Tables S2 and S3.TIAM1 is Regulated by the Canonical WNT Pathway
As stated above, previous studies have shown that a major fac-
tor regulating the stability and nuclear translocation of TAZ is the
destruction complex (Azzolin et al., 2012, 2014), and our afore-
mentioned findings suggested that TIAM1 is also implicated in
this mechanism of TAZ regulation. This prompted us to investi-gate whether TIAM1 was a component of the WNT-regulated
destruction complex. By immunoprecipitating endogenous
TIAM1 from cytosolic and nuclear fractions of confluent
HEK293 cells, which carry a functional destruction complex,
we found that TIAM1 interacted with AXIN, b-catenin, and (as
shown previously by Magliozzi et al. [2014], Zhu et al. [2014],Cancer Cell 31, 621–634, May 8, 2017 625
Figure 4. TIAM1 Regulates TAZ Stability and Nuclear Translocation
(A) Western blot analyses of cytoplasmic (C) and nuclear (N) fractions from confluent HEK293 cells treated with APC or TIAM1#1 siRNAs. Graph showsmean TAZ
and YAP levels normalized to cytoplasmic (a-tubulin) or nuclear (Lamin-B1) markers and then to negative control siRNA (siNT).
(B) Luciferase assay for 8xGTIIC-Lux or control reporter indicating TAZ/YAP-dependent transcriptional activity in confluent HEK293 cells transfected with
TIAM1#1 siRNA, either alone or with two different pairs of TAZ/YAP siRNAs as indicated. Data are normalized to a Renilla reporter and to negative control
siRNA (siNT).
(C) qPCR for TAZ/YAP target genes CTGF and CYR61 normalized to ACTB expression in confluent HEK293 and HaCaT cells transfected with TIAM1#1 siRNA,
either alone or with two different pairs of TAZ/YAP siRNAs as indicated. Data are normalized to negative control siRNA (siNT).
(D)Western blot analyses of endogenous TAZ and TIAM1co-immunoprecipitating (IP) with endogenous bTrCP from confluent HEK293 cells treatedwith TIAM1#1
or TIAM1#2 siRNA. Immunoglobulin G (IgG) was used as a control antibody for immunoprecipitation. Figure is representative of three independent experiments.
Data shown in graphs are presented as mean ± SEM with siNT set as 1 (unpaired t test for three independent experiments: *p < 0.05, **p < 0.01, ***p < 0.001).
See also Figure S4.and above) bTrCP, which are established elements of the
destruction complex as well as TAZ and YAP (Figure 5A). Even
though low levels of TIAM1 were detected in the nucleus,
TIAM1 interaction with AXIN, b-catenin, bTrCP, TAZ, and YAP
was observed only in the cytoplasm of HEK293 cells. The inter-
action of TIAM1 with TAZ was confirmed in vitro using recombi-
nant proteins and was inferred to be direct (Figure 5B).
Since the main function of the destruction complex is
regulating protein stability through degradation, we wondered
whether its inactivation would affect TIAM1 stability. The first
approach we used for inactivation was downregulation of APC
expression by a siRNA (Figure S5A). APC depletion resulted in
a statistically significant increase in TIAM1 levels in the cyto-
plasm of HEK293 cells (Figure 5C). Since TIAM1 mRNA levels
were not increased by APC depletion (Figure S5B), this sug-
gested that APC depletion promoted the stabilization of TIAM1
protein. Interestingly, we also observed a significant increase
in the nuclear levels of TIAM1 (Figure 5C). The stabilization and
nuclear translocation of TIAM1 following APC depletion was
also confirmedby immunofluorescencemicroscopy (Figure S5C)
and is consistent with the nuclear accumulation of TIAM1 we
observe in colorectal tumors (Figure 1A) and CRC cell lines
with defective APC (Figure 2A). As a second approach to inacti-626 Cancer Cell 31, 621–634, May 8, 2017vate the destruction complex, we used conditioned medium
from WNT3A expressing cells. Similar to APC depletion, treat-
ment of confluent RKO cells with WNT3A-conditioned medium
induced the stabilization and translocation of TIAM1 from the
cytoplasm into the nucleus (Figure 5D). Finally, activation of the
WNT pathway by BIO, a small molecule that inhibits GSK3b
activity (Meijer et al., 2003), also induced the stabilization and
nuclear accumulation of TIAM1 in RKO cells (Figure 5E). In sum-
mary, these results indicate that the WNT pathway regulates the
stability and nuclear translocation of TIAM1 through the destruc-
tion complex, as described previously for TAZ (Azzolin et al.,
2012, 2014).
We next addressed how the destruction complex regulates
TIAM1 stability. It is known that bTrCP is responsible for the
degradation of b-catenin (Hart et al., 1999; Kitagawa et al.,
1999; Marikawa and Elinson, 1998) and TAZ (Azzolin et al.,
2012; Huang et al., 2012; Liu et al., 2010). Previous studies
have shown that TIAM1 also interacts with bTrCP, resulting in
its degradation (Magliozzi et al., 2014; Zhu et al., 2014). This
prompted us to investigate whether the increased stabilization
of TIAM1 observed upon WNT3A treatment or APC depletion
is due to its decreased interaction with bTrCP. By carrying out
immunoprecipitations for endogenous bTrCP from confluent
Figure 5. TIAM1 is Regulated by the Canon-
ical WNT Pathway
(A) Western blot analyses of endogenous proteins
co-immunoprecipitating with endogenous TIAM1
from cytoplasmic (C) and nuclear (N) fractions
of confluent HEK293 cells. IgG was used as a
control antibody for immunoprecipitation. Figure is
representative of three independent experiments.
(B) Western blot analyses of increasing amounts
of recombinant TAZ immunoprecipitated with re-
combinant TIAM1. Beads alone, no recombinant
TIAM1, or no recombinant TAZ were used as
negative controls. Figure is representative of three
independent experiments.
(C) Western blot analyses of cytoplasmic (C) and
nuclear (N) fractions from confluent HEK293 cells
transfected with APC siRNA. Lysates from TIAM1-
depleted cells (TIAM1#1 siRNA) were used as
specificity control for the TIAM1 antibody. Graph
shows mean TIAM1 levels normalized to cyto-
plasmic (a-tubulin) or nuclear (Lamin-B1) markers
and then to negative control siRNA (siNT).
(D and E) Representative confocal images of
TIAM1 localization in confluent RKO cells treated
with control or WNT3A-conditioned medium (D)
or control (MeBIO) or GSK3a inhibitor (BIO) (E).
Images are representative of three independent
experiments. Scale bars, 10 mm.
(F) Western blot analyses of endogenous
TIAM1 and TAZ co-immunoprecipitating (IP) with
endogenous bTrCP from confluent HEK293 cells
treatedwith APC siRNA. IgGwas used as a control
antibody for immunoprecipitation. Graph shows
average bTrCP/TIAM1 or bTrCP/TAZ interaction
from three independent replicates.
(G) Western blot analyses of endogenous proteins
co-immunoprecipitating with endogenous TIAM1
from confluent HEK293 cells treated with WNT3A
conditioned medium for different time points as
indicated. IgG was used as a control antibody for
immunoprecipitations. Figure is representative of
three independent experiments.
Data shown in graphs are presented as mean ±
SEM with siNT set as 1 or 100% (unpaired t test
for three independent experiments: *p < 0.05,
***p < 0.001). See also Figure S5.control or APC-depleted HEK293 cells, we found that the inter-
action of TIAM1 with bTrCP was almost abolished in cells in
which APC was depleted (Figure 5F). A dramatic decrease in
the interaction between TAZ and bTrCP was also observed un-
der these conditions (Figure 5F). Furthermore, following activa-
tion of the WNT pathway by WNT3A treatment, TIAM1 interac-
tion with proteins of the destruction complex including AXIN
and bTrCP, as well as TAZ, was abolished (detected from
0.5 hr; Figure 5G). Taken together, these data imply that activa-
tion of the canonical WNT pathway (inactivation of the destruc-
tion complex) induces TIAM1 stability and nuclear translocation
by regulating the interaction between TIAM1 and bTrCP.
Nuclear TIAM1Antagonizes TAZTranscriptional Activity
The role of TIAM1 in promoting TAZ degradation by the destruc-
tion complex could offer one explanation for the stimulation of
TAZ transcriptional activity following TIAM1 depletion (Figures
4B and 4C). However, our findings also indicated that TIAM1 an-tagonizes TAZ transcriptional activity in CRC cells with a consti-
tutively defective destruction complex (Figure 3), pointing to an
additional mechanism by which TIAM1 antagonizes TAZ. Since
inactivation of the destruction complex induces nuclear translo-
cation of both TIAM1 and TAZ, we hypothesized that the two
proteins might also interact in the nucleus, potentially interfering
with TAZ transcriptional activity. Immunoprecipitation of endog-
enous TIAM1 from control or APC-depleted HEK293 cells re-
vealed that inactivation of the destruction complex indeed re-
sulted in the appearance of a nuclear TIAM1/TAZ complex
accompanied by reduction of this complex in the cytoplasm (Fig-
ure 6A). An interaction between TIAM1 and TAZ could also be
detected in nuclear extracts from three different CRC cell lines
(Figures 6B, S6A, and S6B), and was confirmed by Duolink prox-
imity ligation assay (Figure 6C). Next, we tested the effect of
TIAM1 knockdown on TAZ transcriptional activity in these CRC
cells. Similar to HEK293 and HaCaT cells (Figures 4C and
S4E–S4G), TIAM1 depletion in SW620 and DLD1 cells stronglyCancer Cell 31, 621–634, May 8, 2017 627
Figure 6. Nuclear TIAM1 Antagonizes TAZ Transcriptional Activity
(A) Western blot analyses of endogenous TAZ co-immunoprecipitating (IP) with endogenous TIAM1 from cytoplasmic (C) and nuclear (N) fractions of confluent
HEK293 cells treated with APC or a negative control (siNT) siRNA. IgG was used as a control antibody for immunoprecipitation. Graph shows mean levels of
immunoprecipitated TAZ normalized to levels of immunoprecipitated cytoplasmic or nuclear TIAM1.
(B) Western blot analyses of endogenous TAZ co-immunoprecipitating with endogenous TIAM1 from cytoplasmic (C) and nuclear (N) fractions of DLD1 cells. IgG
was used as a control antibody for immunoprecipitation. Figure is representative of three independent experiments.
(C) Representative confocal images from three independent experiments of TAZ/TIAM1 interaction in parental SW480 cells detected by Duolink assay. Staining in
one CRISPR-mediated TIAM1 knockout clone (TIAM1-KO#1) was used as a control for antibody specificity. Scale bars, 10 mm.
(D) qPCR for the TAZ/YAP target genesCTGF andCYR61 normalized toACTB expression in SW620 and DLD1 cells transfected with TIAM1#1 siRNA alone, TAZ/
YAP siRNAs alone, or a combination of TIAM1#1 siRNA and TAZ/YAP siRNAs as indicated. Data are normalized to negative control siRNA (siNT).
(E) Western blot analyses of endogenous TAZ co-immunoprecipitating with endogenous TEAD from nuclear fractions of parental SW480 cells or the CRISPR-
mediated TIAM1 knockout clones. IgGwas used as a control antibody for immunoprecipitation. Graph showsmean levels of immunoprecipitated TAZ normalized
to levels of immunoprecipitated TEAD.
(legend continued on next page)
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induced the expression of CTGF and CYR61, which could be
suppressed by depletion of endogenous YAP and TAZ (Figures
6D and S6C), indicating that TIAM1 inhibits the transcriptional
activity of YAP and TAZ in CRC cells.
The antagonistic effect of nuclear TIAM1 on TAZ/YAP activity
prompted us to examine whether nuclear TIAM1 might prevent
the interaction of TAZ and YAP with TEADs. Immunoprecipitat-
ing endogenous TEADs from nuclear extracts of parental
SW480 cells or the two CRISPR-mediated TIAM1 knockout
SW480 clones revealed that TIAM1 ablation increased the inter-
action of TEADswith TAZ and YAP (Figures 6E and S6D). Duolink
proximity ligation assays confirmed that the interaction between
TAZ or YAP with TEADs was increased in the absence of TIAM1
(Figures 6F and S6E). The inhibitory effect of nuclear TIAM1 on
TAZ activity was further demonstrated by chromatin immuno-
precipitation sequencing (ChIP-seq) analysis. Parental SW480
cells or the TIAM1 knockout SW480 clone #1 cells were used
to determine the recruitment of TAZ to chromatin in the presence
or absence of TIAM1. We found that the number of TAZ peaks
identified in the TIAM1 knockout cells (35,450 peaks) was
increased compared with the parental cells (24,913 peaks)
(GEO: GSE90492). As shown in Figure S6F, of the total peaks
discovered by MACS peak caller, a subset of the peaks were
exclusively found in either the TIAM1 knockout SW480 clone
#1 cells (23,849 peaks) or parental cells (13,101 peaks). We
then examined locations with overlapping TAZ peaks. In total
there were 5,740 overlapping peaks, of which 2,082 had higher
(>1.5 fold) TAZ recruitment to the chromatin in the TIAM1
knockout cells compared with parental cells (Figure 6G). In
contrast, only 84 peaks were found to have a higher TAZ recruit-
ment in the parental cells. Furthermore, consistent with the
above findings that TIAM1 knockdown induces the interaction
of TAZ with TEAD and induces the expression of CYR61, we
found that deletion of TIAM1 increased the binding of TAZ to
the promoter region of CYR61 (Figure 6H). Taken together, our
results indicate that nuclear TIAM1 functions as a negative regu-
lator of the transcriptional activity of TAZ and YAP.
The Effect of Nuclear TIAM1 on CRC Cell Proliferation,
Migration, and In Vivo Invasion
Having demonstrated that TIAM1 antagonizes TAZ/YAP tran-
scriptional activity, we analyzed the functional significance of
their interaction. Previous studies have shown that both TIAM1
and TAZ/YAP regulate cell proliferation and migration (Minard
et al., 2004; Malliri et al., 2006; Zanconato et al., 2016). First,
we evaluated the potential effect of TIAM1 depletion on the pro-
liferation of CRC cell lines and their dependence on TAZ/YAP.
TIAM1, TAZ/YAP, or a combination of all three was depleted us-
ing siRNAs, and cell number was determined 6 days post trans-
fection. As shown in Figure S7A, downregulation of either TAZ/
YAP or TIAM1 decreased the proliferation of DLD1, SW480,
and SW620 cells. However, the combined depletion of TIAM1(F) Representative confocal images from three independent experiments of TA
knockout clones detected by Duolink assay. Scale bars, 10 mm.
(G) Heatmap depiction of TAZ recruitment to chromatin of parental or CRISPR-m
(H) Read density tracks of TAZ ChIP-seq enrichment in CYR61 locus of parental
Data shown in graphs are presented as mean ± SEM with siNT or parental set as 1
*p < 0.05, **p < 0.01, ***p < 0.001). See also Figure S6.and TAZ/YAP on the proliferation of CRC cells was not additive,
indicating that the effect of TIAM1 depletion on cell proliferation
is TAZ/YAP independent.
To investigate specifically the role of nuclear TIAM1 on cell
proliferation, we generated an NLS-TIAM1 construct by fusing
full-length TIAM1 with the well-characterized NLS of SV40 large
T antigen. We verified that the NLS-TIAM1 construct was exclu-
sively nuclear compared with full-length TIAM1 (FL-TIAM1) (Fig-
ure S7B). Expression of NLS-TIAM1 (resistant to siTIAM1#1) at
levels comparable with endogenous TIAM1 in DLD1 or SW620
cells had no effect on the proliferation of TIAM1-depleted cells
(Figure S7C). However, FL-TIAM1 partially restored proliferation
in TIAM1-depleted cells. Similarly, expression of FL-TIAM1, but
not NLS-TIAM1, in SW480 CRISPR-mediated TIAM1 knockout
cells restored proliferation to levels observed in parental cells
(Figure S7D). Taken together, these results indicate that the ef-
fect of TIAM1 depletion on cell proliferation is TAZ/YAP indepen-
dent and not related to its nuclear localization.
We next investigated the potential effect of TIAM1 depletion
on the migration of SW480 and SW620 cells and its dependence
on TAZ/YAP. TIAM1, TAZ/YAP, or a combination of all three was
depleted using siRNAs, and cells were assayed for their migra-
tory potential over 24 hr using the Boyden chamber assay.
As shown in Figure 7A, TIAM1 depletion in both SW480 and
SW620 cells induced a strong migratory response. Interestingly,
this increase in migration was dependent on TAZ/YAP, as deple-
tion of endogenous YAP and TAZ dramatically reduced the effect
of TIAM1 depletion (Figure 7A). To verify that specifically nuclear
TIAM1 suppresses cell migration, we analyzed the migratory
capacity of SW480 cells overexpressing NLS-TIAM1. Notably,
compared with parental SW480 cells, cells expressing NLS-
TIAM1 migrated significantly less (Figure 7B). Furthermore,
overexpression of NLS-TIAM1 abolished the increased migra-
tion observed in the two CRISPR-mediated TIAM1 knockout
SW480 clones (Figure 7B).
To investigate the role of nuclear TIAM1 on migration in vivo,
we turned to a zebrafish xenograft model. Fluorescently labeled
parental SW480 cells or the aforementioned SW480 CRISPR-
mediated TIAM1 knockout cells inducibly expressing either FL-
TIAM1 or NLS-TIAM1 (Figure S7D) were injected into the pericar-
dial cavity of 2-day-old zebrafish embryos. Ninety-six hours after
injection, tumor cells were observed to have largely filled the
approximately conical-shaped cavity (excluding the volume
occupied by the heart) in all cases. Compared with parental
SW480 cells, significantly more non-induced (minus doxycycline
[Dox]) SW480 TIAM1 knockout cells disseminated away from
the pericardial region (Figure 7C), whereas cells expressing
(plus Dox) either FL-TIAM1 or equally NLS-TIAM1 showed a
decreased ability to disseminate (Figure 7C), indicating the inhib-
itory role of nuclear TIAM1 on invasion. Taken together, these re-
sults suggest that nuclear TIAM1 suppresses TAZ/YAP-induced
cell migration and in vivo invasion of CRC cells.Z/TEAD interaction in parental SW480 cells or the CRISPR-mediated TIAM1
ediated TIAM1-knockout clone #1 (TIAM1-KO#1) SW480 cells.
or CRISPR-mediated TIAM1-KO#1 SW480 cells.
in (D) and (E), respectively (unpaired t test for three independent experiments:
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Figure 7. Effect of TIAM1 on Cell Migration and In Vivo Invasion
(A) Representative images of SW480 cells or SW620 cells migrating through Transwell inserts toward serum for 24 hr. Cells were transfectedwith siRNA for TIAM1
or TAZ/YAP either alone or in combination, as indicated. Scale bars, 150 mm. Graphs show average number of migrating cells normalized to negative control
siRNA (siNT) and are presented as mean ± SEM (with siNT set as 100) (unpaired t test: *p < 0.05, ***p < 0.001).
(B) Representative images of parental SW480 or the CRISPR-mediated TIAM1 knockout clones (TIAM1-KO #1 and # 2) migrating through Transwell inserts
toward serum for 24 hr. Cells were transfected with NLS-TIAM1 or empty vector (EV) as control. Scale bars, 150 mm. Graph shows average number of migrating
cells normalized to EV and are presented as mean ± SEM (EV transfected parental cells set as 100) (unpaired t test: *p < 0.05, ***p < 0.001).
(C) Representative images at 4 days post injection of parental green fluorescent SW480 and SW480-TIAM1-KO#1 cells, non-induced (Minus Dox), or inducibly
expressing (Plus Dox) either FL-TIAM1 or NLS-TIAM1 engrafted into the pericardial cavity of zebrafish embryos. Upper row shows epifluorescence of injected
cells. White dotted line indicates the pericardial cavity. Lower row shows merge with bright field. Scale bar, 100 mm. Graphs show quantitation of invasion. Mean
values ± SEM from three independent experiments (Kruskal-Wallis one-way ANOVA and Dunn’s post hoc test: *p < 0.05, **p < 0.01).
See also Figure S7.DISCUSSION
Herein, we present evidence indicating that TIAM1 suppresses
CRCcell migration and invasion by regulating TAZ/YAP transcrip-630 Cancer Cell 31, 621–634, May 8, 2017tional activity. Furthermore, we propose that this function of
TIAM1 underpins our earlier observation that TIAM1 antagonizes
malignant progression of intestinal neoplasia in the ApcMin/+
mouse model (Malliri et al., 2006). Interestingly, we found that
Figure 8. Model Depicting the Proposed
Mechanism of TIAM1-Mediated Regulation
of TAZthe role of TIAM1 in regulating TAZ/YAP entails not only functions
performed in the cytoplasm but also events in the nucleus, and
propose the following model (Figure 8). (1) In the absence of
WNT signaling, TIAM1 and TAZ are collectively recruited to the
destruction complex for targeted ubiquitylation and degradation.
(2) UponWNT stimulation (or following initiating oncogenic events
that inactivate the destruction complex), both TIAM1 and TAZ are
released from the destruction complex and stabilized, and trans-
locate to the nucleus. However, TAZ transcriptional activity is still
greatly suppressed by the nuclear pool of TIAM1, impairing the
interactionof TAZwithTEADs. (3)UponWNTstimulation/inactiva-
tion of the destruction complex and in the absence of TIAM1, TAZ
present in the nucleus transactivates the TEAD transcriptional
program, which in the context of neoplasia would promote a
more malignant phenotype.
One of the main findings of this study is that TIAM1 associates
with the destruction complex. Inactivation of the destruction
complex by various means was shown to promote TIAM1 accu-
mulation and, concomitantly, its nuclear translocation. We
further demonstrated that TIAM1 modulates the interaction be-
tween TAZ and bTrCP, influencing TAZ stability. As TIAM1 and
bTrCP interact (Magliozzi et al., 2014; Zhu et al., 2014) as do
TIAM1 and TAZ, it is probable that TIAM1 functions as a physical
scaffold bringing TAZ and bTrCP into proximity. Whether TIAM1
directly interacts with AXIN, the main structural component of
the destruction complex, or APC is presently unknown. How-
ever, the ability to immunoprecipitate a complex containing all
these components suggests that the interactions are relatively
stable.
The destruction complex is a key checkpoint for regulating ca-
nonical WNT signaling. Inactivation of the destruction complex
liberates two different effectors: the well-documented b-catenin
(Clevers, 2006) and recently implicated TAZ/YAP (Azzolin et al.,
2012, 2014). Indeed, both transcriptional co-activators appear
to be required for expression of WNT target genes in intestinal
epithelial progenitor cells and CRC cells (Azzolin et al., 2012;
Fevr et al., 2007). However, the identities of the transcription fac-
tor complexes that regulate subsets of WNT-induced targetgenes responsible for distinct WNT-
mediated biological responses (such as
stem cell maintenance, transit amplifica-
tion, EMT, or terminal differentiation)
have not been fully delineated. Previous
studies have shown that TAZ is not
required for b-catenin/TCF-dependent
transcription (Azzolin et al., 2012; Imajo
et al., 2015) and conversely that TAZ/
YAP transactivation is independent of
b-catenin/TCF (Imajo et al., 2015). None-
theless, a complex between b-catenin
and TAZ/YAP that includes the tran-
scription factor TBX5 and is critical
for b-catenin-driven transformation hasbeen described (Rosenbluh et al., 2012). These studies indicate
the complexity of the system and suggest that additional studies
are required to fully uncover the transcriptional molecular mech-
anisms that regulate CRC initiation and progression.
Our study sheds light on TAZ/YAP function in CRC progres-
sion. Our results showed that nuclear TIAM1 plays a critical
role in regulating the TAZ/YAP transcriptional program that is
responsible for cell migration, with TIAM1 suppressing this pro-
gram evenwhen theWNT pathway is activated. Interestingly, the
inhibitory nuclear function of TIAM1 on TAZ/YAP transcriptional
activity is not associated with cell proliferation. Since one of
the main molecular signatures that were enriched in the
TIAM1-depleted cells was associated with EMT, we speculate
that TIAM1 may be associated with suppressing cancer stem
cell identity, since cancer stem cells are characterized by a
mesenchymal cell gene expression program (Oskarsson et al.,
2014). Furthermore, TAZ and YAP have been implicated in the
expansion of stem cells in the regenerating gut but also in adeno-
matous polyps (Cai et al., 2010; Gregorieff et al., 2015). Our
previous work revealed a gradient of TIAM1 expression highest
toward the bottom of intestinal crypts, overlapping with the
stem cell and transit amplification (TA) compartments (Malliri
et al., 2006). In accordance with TIAM1 playing a role in sup-
pressing stemness in the TA compartment through inhibiting
TAZ/YAP, in this study we found that the TIAM1 knockout-medi-
ated induction of the TAZ target genes CTGF and CYR61 was
predominantly observed in the expanded crypts of APC-defi-
cient intestines.
Different studies have shown that APC loss alone is insuffi-
cient to promote intestinal tumor progression (Anderson et al.,
2002; Blaker et al., 2003); additional mutations in other onco-
genes such as KRAS and tumor-suppressor genes such as
TP53 are required (Fujii et al., 2016). Our results suggest that
TIAM1 is an additional protein that needs to be inactivated dur-
ing CRC progression. In support of this statement, our clinical
data revealed that TIAM1 expression levels decline with disease
progression and that patients having CRC with high levels of
nuclear TIAM1 survive longer. Based on the outcome of cancerCancer Cell 31, 621–634, May 8, 2017 631
genome resequencing, TIAM1 downregulation is not typically
achieved through mutation. Downregulation could be achieved
at the transcriptional level or post-translationally. Previous work
has shown that oncogenic RAS expression suppresses TIAM1
transcription (Zondag et al., 2000). Furthermore, we and others
have identified E3 ubiquitin ligases targeting TIAM1 for degrada-
tion (Genau et al., 2015; Magliozzi et al., 2014; Vaughan et al.,
2015; Zhu et al., 2014), which may be deregulated in intestinal
carcinoma. Potentially, factors resulting in exclusion of TIAM1
from the nucleus might also result in downregulation of this
critical suppressor function of TIAM1, and we are currently
investigating the mechanisms regulating TIAM1 nuclear import
and export. Previous studies have indicated that YAP and
TAZ expression is increased in CRC (especially high-grade
CRC), and their expression may be used as a prognostic marker
(Cai et al., 2010; Wang et al., 2013; Yuen et al., 2013). However,
TAZ/YAP expression levels might not be a sufficient prognostic
marker for CRC patients, as differences in nuclear levels
of TIAM1 might differentially affect the transcriptional activity
of TAZ/YAP. An index based on both TAZ/YAP expression
and nuclear TIAM1 intensity could therefore provide clearer
prognostication.STAR+METHODS
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Rabbit anti-TIAM1 Antibody, Affinity Purified Bethyl Laboratories, Inc. Cat# A300-099A RRID:AB_2271617
Polyclonal Sheep Human/Mouse TIAM1 Antibody R&D Systems Cat# AF5038 RRID:AB_2303175
Purified Mouse anti-TAZ Clone M2-616 (RUO) BD Biosciences Cat# 560235 RRID:AB_1645338
Anti-WWTR1 antibody produced in rabbit Sigma-Aldrich Cat# HPA007415 RRID:AB_1080602
YAP (D8H1X) XP Rabbit mAb Cell Signaling Technology Cat# 14074
Lamin B1 (D4Q4Z) Rabbit mAb Cell Signaling Technology Cat# 12586
b-TrCP (D13F10) Rabbit mAb Cell Signaling Technology Cat# 4394S RRID:AB_10545763
Anti-BTRC Antibody (1B1D2) Invitrogen Cat# 373400 RRID:AB_431439
Axin1 (C76H11) Rabbit mAb Cell Signaling Technology Cat# 2087 RRID:AB_2274550
b-Catenin (D10A8) XP Rabbit mAb Cell Signaling Technology Cat# 8480 RRID:AB_11127855
Anti-TEAD4 antibody - ChIP Grade Abcam Cat# ab58310 RRID:AB_945789
Pan-TEAD (D3F7L) Rabbit mAb Cell Signaling Technology Cat# 13295
CTGF Antibody (L-20) goat polyclonal Santa Cruz Biotechnology Cat# sc-14939 RRID:AB_638805
Mouse anti-a-Tubulin Monoclonal antibody, Clone DM1A Sigma-Aldrich Cat# T9026 RRID:AB_477593
Rabbit Anti-CTGF antibody Polyclonal antibody Abcam Cat# ab6992 RRID:AB_305688
Anti-CCN1 (CYR61) antibody Abcam Cat# ab24448 RRID:AB_2088724
Biological Samples
CRC TMA Prof. Graeme I. Murray Brown et al., 2014
Chemicals, Peptides and Recombinant Proteins
Recombinant TAZ Abnova Cat# H0006901-P01
BIO Tocris Bioscience Cat# 3194
MeBIO Tocris Bioscience Cat# 3873
NUPAGE 3-8% TA GEL 1.0MM10W ThermoFischer Scientific Cat# EA0375BOX
GammaBindTM G SepharoseTM GE Healthcare Life Sciences Cat# GE17-0885-01
Doxycycline Sigma-Aldrich Cat# D9891
Lipofectamine RNAiMAX Transfection Reagent ThermoFischer Scientific Cat# 13778075
TransIT-LT1 Transfection Reagent Mirus Cat# MIR 2300
PfuUltra II Fusion HS DNA Polymerase Agilent Technologies Cat# #600672
Tamoxifen Sigma-Aldrich Cat# H7904





RNeasy Mini Kit Qiagen, UK Cat# 74104
Omniscript RT Kit Qiagen, UK Cat# 205111
QuikChange II XL Site-Directed Mutagenesis Kit Agilent Technologies Cat# 200522
Dual-Luciferase Reporter Assay System Promega Cat# E1910
SimpleChIP Enzymatic Chromatin IP Kit
(Magnetic Beads)
Cell Signaling Technology Cat# 9003
MicroPlex Library Preparation Kit v2 Diagenode Cat# C05010014
Duolink In Situ Red Starter Kit Mouse/Rabbit Sigma-Aldrich Cat# DUO92101
Duolink In Situ Red Starter Kit Goat/Rabbit Sigma-Aldrich Cat# DUO92105
Deposited Data
RNA-seq and ChIP-seq data This study GEO: GSE90492
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CaCo2 Gift from Prof Hans Clevers N/A
DLD1 Gift from Prof Hans Clevers Authenticated by MBCF of CRUK MI
SW480 Gift from Prof Hans Clevers Authenticated by MBCF of CRUK MI
SW620 Gift from Prof Hans Clevers Authenticated by MBCF of CRUK MI
HEK293 ECACC (operated by Public
Health England)
Cat# 85120602
HaCaT Gift from Dr Vania Braga N/A
RKO Prof Owen Sansom lab N/A
L-WNT3a cells Prof Owen Sansom lab N/A
L-Control cells Prof Owen Sansom lab N/A
SW480-TIAM1-KO#1 This study N/A
SW480-TIAM1-KO#2 This study N/A
SW480-TIAM1-KO#1-FL-TIAM1 This study N/A
SW480-TIAM1-KO#1-NLS-TIAM1 This study N/A
DLD1-FL-TIAM1(siRNA resistant) This study N/A
DLD1-NLS-TIAM1(siRNA resistant) This study N/A
SW620-FL-TIAM1(siRNA resistant) This study N/A
SW620-NLS-TIAM1(siRNA resistant) This study N/A
Experimental Models: Organisms/Strains
Mouse: Apc580S Sansom et al., 2007 N/A
Mouse: Vil-Cre-ER el Marjou et al., 2004 N/A
Mouse: Tiam1-/- Malliri et al., 2002 N/A




pSpCas9(BB)-2A-GFP Ran et al., 2013 Addgene Plasmid #48138
pSpCas9(BB)-2A-GFP-TIAM1-KO This study N/A
pRetroX-Tight-Pur Clontech Cat# PT3968-5
pRetroX-Tight-Pur-FL-TIAM1 This study N/A
pRetroX-Tight-Pur-NLS-TIAM1 This study N/A
pRetroX-Tight-Pur-FL-TIAM1(siRNA resistant) This study N/A
pRetroX-Tight-Pur-NLS-TIAM1(siRNA resistant) This study N/A
pcDNA3-NLS-TIAM1 This study N/A
pEGFP-N3 FL-TIAM1 This study N/A
pEGFP-N3 FL-TIAM1-DNLS2 This study N/A
pEGFP-N3 TIAM1-m1 This study N/A
pEGFP-N3 TIAM1-m2 This study N/A
pEGFP-N3 TIAM1-m3 This study N/A
pGL3-8xTEAD Firefly vector Dr Georges Lacaud lab N/A
pGL3-Control Firefly vector Dr Georges Lacaud lab N/A
pGL4 Renilla vector Dr Georges Lacaud lab N/A
Software and Algorithms
Universal ProbeLibrary Assay Design Center Roche https://lifescience.roche.com/en_gb/brands/
universal-probe-library.html
Human reference genome NCBI build 37, GRCh37 Genome Reference Consortium http://www.ncbi.nlm.nih.gov/projects/genome/
assembly/grc/human/
Bowtie2 (version 2.2.1) Langmead and Salzberg, 2012 http://bowtie-bio.sourceforge.net/bowtie2/
index.shtml
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Tophat2 (version 2.0.12) Kim et al., 2013 http://ccb.jhu.edu/software/tophat.
Bioconductor package Rsubread (version 1.13.13) Liao et al., 2014 https://bioconductor.org/packages/release/
bioc/html/Rsubread.html
Bioconductor package edgeR (version 3.8.5) Robinson et al., 2010 https://bioconductor.org/packages/release/
bioc/html/edgeR.html
MACS2 (version 2.1.0.20150420) Zhang et al., 2008 https://pypi.python.org/pypi/MACS2/
2.1.0.20150420
GenomicRanges Ramirez et al., 2014 http://bioconductor.org/packages/release/bioc/
html/GenomicRanges.html
Deeptools Lawrence et al., 2013 http://deeptools.ie-freiburg.mpg.de
GraphPad Prism version 6.0 GraphPad Software Inc http://www.graphpad.com/scientific-software/
prism/
IBM SPSS statistics 23 IBM http://www-01.ibm.com/support/
docview.wss?uid=swg24038592
Volocity Software version 6.0.1 Perkin Elmer, Cambridge, UK http://ftparmy.com/248712-volocity.htmlCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact Angeliki
Malliri (Angeliki.Malliri@cruk.manchester.ac.uk)
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mouse Experiments
All experimental procedures were performed under National HomeOffice guidelines andwere approved by the ethical review body of
Glasgow University. The Vil-Cre-ER experiments were performed on a mixed background (50% C57Bl6J, 50% S129). The alleles
used for this study were as follows: Apc580S (Sansom et al., 2007), Vil-Cre-ER (el Marjou et al., 2004) and Tiam1-/- (Malliri et al.,
2002). Recombination by Vil-Cre-ERwas achieved by intraperitoneal (i.p) injection of 80mg/kg tamoxifen per day for 2 days. Analysis
of Vil-Cre-ER induced mice was carried out at day 4 post induction, where the intestine was placed in 10% normal buffered formalin
for 16-18 hr at 4C. Immunohistochemical analysis was performed using standard techniques. Primary antibodies and concentra-
tions were used as follows: CTGF (1:200; Abcam, 6992) and CYR61 (1:100; Abcam, 24448).
Zebrafish Xenograft Assay
Adult zebrafish (Danio rerio) were maintained at The University of Manchester Biological Services Unit. Experiments were performed
according to National Home Office regulations under the Animals (Scientific Procedures) Act 1986 and were approved by the ethical
review body of The University of Manchester. Casper strain (roy-/-, nacre-/-) zebrafish were used to generate embryos completely
lacking pigment which can otherwise obscure imaging. SW480 cell lines were resuspended at 1.4 x 107 cells/ml on ice with PBS
(w/o CaCl2 and MgCl2) supplemented with 0.5% polyvinylpyrrolidinone K60 solution (PVP, Sigma). 48 hr post fertilization (hpf) em-
bryos were anaesthetised with 0.1mg/ml MS-222 (Sigma) and approximately 500 cells were injected into the pericardial cavity, using
a micropipette and pump (World Precision Instruments). Engrafted embryos were sorted to remove falsely injected embryos and as
needed, treated with 1 mg/ml doxycycline (Fisher Scientific) and maintained at 34C for a further 4 days. At 4 days post injection (dpi)
engrafted zebrafish embryos were anaesthetised in 0.1 mg/ml MS-222, mounted in 1.5% low melting agarose (LMP, Promega) and
xenografts imaged using a Leica TCS SP5 AOBS upright confocal (Leica Microsystems) using a 20x 0.50 Plan Fluotar dipping objec-
tive and 1.0x confocal zoom. Z stacks from the top to the bottom of the tumor were captured and processed using Volocity Software
version 6.0.1 (Perkin Elmer) with the Volocity Visualization module and standard parameters. All experiments consist of three inde-
pendent repeats. Relative Invasion Index is defined as the number of cells invaded outside the pericardial cavity at 4 dpi normalized to
the average number of invading cells in the control group.
TMA Immunohistochemical Analysis
Immunohistochemistry for TIAM1 (1:700; R&D Systems, AF5038) was performed with a standard avidin-biotin complex method
(ABC) on a colorectal cancer tissue microarray (TMA) containing 650 primary colorectal cancers all of which were histologically ad-
enocarcinomas. TMA samples were obtained from the Grampian Biorepository with ethical approval from the scientific access group
of the Grampian Biorepository (tissue request number TR72). The design and construction of the TMA has previously been described
(Brown et al., 2014). Clinico-pathological details of the patients and the colorectal cancers included in the tissue microarray areCancer Cell 31, 621–634.e1–e6, May 8, 2017 e3
summarized in Table S1. None of the patients had received either pre-operative chemotherapy or radiotherapy. Following completion
of the TIAM1 immunohistochemistry the TMA slides were examined by an expert gastro-intestinal pathologist (GIM) by light micro-
scopy using an Olympus BX 51 microscope (Olympus) equipped with an Olympus C4040 digital camera (Olympus). The intensity of
immunostaining was quantified using a semi-quantitative scoring method as previously described (Brown et al., 2014). The intensity
of immunostaining (negative, weak, moderate, strong) and its subcellular localization (cytoplasmic, nuclear, membranous) was as-
sessed. Statistical analysis including survival analysis was performed using IBM SPSS statistics 23.
Cell Lines
DLD1 cells were cultured in RPMI supplemented with 10% fetal bovine serum, Penicillin and Streptomycin. The rest of the cells lines
were cultured in Dulbecco’s Modified Eagle Medium supplemented with 10% fetal bovine serum, Penicillin and Streptomycin. Cell
lines were maintained in a 5% CO2 incubator at 37
C. Cell lines were routinely tested to exclude Mycoplasma contamination.
METHOD DETAILS
Quantitative PCR (qPCR)
1 mg of RNA was reverse transcribed to cDNA using the Omniscript RT Kit (Qiagen) according to the manufacturer’s instructions.
qPCRwas performed in triplicate in a 10 ml reactionmixture containing 5 ml of 23 TaqManmaster mix, 0.5 mMof each of the primers
and 10 ng cDNA. The reaction mixture without a template was run as a control. ACTB expression levels were used to normalize for
differences in RNA input. Primers for ACTB, APC, CTGF, CYR61 and TIAM1 were designed online using the Universal ProbeLibrary
Assay Design Center and listed in Table S4. For the rest of the genes predesigned TaqManGene Expression Assays (ThermoFisher
Scientific) were used (AMOTL2 #Hs01048101_m1, ANKRD1 #Hs00173317_m1, AXL #Hs01064444_m1 and WWTR1 (TAZ)
#Hs00210007_m1).
RNA-Sequencing
Paired-end sequence (75 bp) were aligned to the human reference genome GRCh37 (Ensembl v75) using Tophat2 (version 2.0.12)
(Kim et al., 2013) with the additional settings ‘‘–library-type fr-firststrand –no-novel-junc’’. Mapped reads of the same samples across
different lanes were merged into one BAM file. The expression levels of 57,773 annotated features were determined by using the
featureCounts (Liao et al., 2014) function from the Bioconductor package Rsubread (version 1.13.13). The Bioconductor package
edgeR (Robinson et al., 2010) (version 3.8.5) was used to identify genes that showed statistically significant variation in expression
levels in the following siRNA induction: siTIAM1 versus siNT or siYAP/TAZ versus siNT. The data was filtered to include only genes
with at least 1 count-per-million reads and differential expression analysis was performed using the function exactTest in edgeR
(Robinson et al., 2010) (> 1.5 fold change, false discovery rate < 0.05).
Construction of Expression Vectors
A series of mutant pEGFP-N3 TIAM1 constructs were generated by PCR mutagenesis using pFU ultra II and QuikChange II XL Site-
DirectedMutagenesis Kit (Agilent) for amino acid deletions or substitutions according to themanufacturer’s instructions. The primers
used in the PCR reactions are listed in Table S4. For theNLS-TIAM1 construct, PCRwas used to replace the start codon of TIAM1-HA
in pcDNA3 with 5’ NLS (ATGGGTCCTCCAAAAAAGAAGAGAAAGGTA) and then NLS-TIAM1 from pcDNA3 was cloned into pRETRO
X-Tight (Clontech) using appropriate restriction enzyme digests.
Generation of TIAM1 Knock-Out Cell Lines
A TIAM1 sgRNA sequence (5’-GCTCATCGCTGTGCGCCGAGC-3) was cloned into the pSpCas9(BB)-2A-GFP (PX458) vector (Addg-
ene, #48138) and transfected into SW480 cells using Lipofectamine 2000 (Invitrogen). 48 hr later, single GFP positive cells were
sorted and plated into 96-well plates. Surviving clones were screened for expression levels of TIAM1 by immunoblotting. Disruption
of TIAM1 locus was confirmed by Sanger sequencing.
Generation of DLD1, SW620 and SW480 Cells Inducibly Overexpressing FL-TIAM1 or NLS-TIAM1
Phoenix cells were transfected with either pRETRO X-Tight-FL-TIAM1 or pRETRO X-Tight-NLS-TIAM1 constructs, using TransIT-
LT1 (Mirus) according to the manufacturer’s instructions. Retroviral transduction was performed as previously described (Woodcock
et al., 2009) and transfections were followed by appropriate antibiotic selection.
Transient siRNA Silencing
Transient silencing of TIAM1, TAZ, YAP or APC was achieved by transfection of siRNA oligos using Lipofectamine RNAiMAX (Invi-
trogen) following the manufacturer’s instructions. Cells were transfected 24 hr after seeding, re-transfected on day 4 and processed
and analyzed 6 days after the first transfection by when cells had reached full confluency. Two different siRNA sequences were used
for YAP1 (Ambion, #s20367 and #s20366) and TAZ (Ambion, #s24789 and #s24787) and a single siRNA for APC (Ambion, #s1433).
For TIAM1, two siRNA sequences were used (#1 5’-GAGGUUGCAGAUCUGAGCA-3’, #2 5’-AGAGCGCACCUACGUGAAA-3’) and
synthesized by Eurofins MWG. In all of the reported assays, a negative control siRNA was used (Ambion, Negative Control #1).e4 Cancer Cell 31, 621–634.e1–e6, May 8, 2017
Luciferase Assays
Firefly luciferase reporters (100 ng) were transfected together with Renilla Luciferase reporters (100 ng) to normalize the transfection
efficiency. For luciferase assays in siRNA-depleted cells, cells were first transfected with the indicated siRNAs and, after 24 hr, with
plasmid DNA. Each sample was transfected in duplicate, and each experiment was repeated at least three times independently.
Luciferase was measured 48 hr post-transfection of HEK293.
Nuclear Fractionation
For nuclear fractionation cells were incubated in Hypotonic Buffer (20 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2) for 15 min
on ice and then 10% NP-40 was added to make a 0.5% buffer. After a 10 min centrifugation at 800 g, the cytoplasmic fraction
(the supernatant) was collected. The nuclear pellet was resuspended in Cell Extraction buffer (ThermoFisher Scientific, FNN0011)
and incubated on ice for 30 min. Finally, the nuclear fraction was collected after a 30 min centrifugation at 14,000 g to remove the
insoluble material. All buffers contained a protease inhibitor cocktail (Sigma) and phosphatase inhibitor cocktails 2 and 3 (Sigma).
Immunoprecipitation
Protein G beads were pre-blocked with an equal volume of 5% BSA/PBS to make a 50% Protein G slurry. Cells were lysed in immu-
noprecipitation lysis buffer [50mMTris-HCl pH 7.5, 150mMNaCl, 1% (v/v) Triton-X-100, 10% (v/v) glycerol, 2mMEDTA, 25mMNaF
and 2 mM NaH2PO4] containing protease and phosphatase inhibitor cocktails (Sigma). Lysates were pre-cleared using IgG-conju-
gated Protein G beads, incubated with the specific antibodies for 2 hr at 4C and then incubated with beads for 1 hr at 4Cwith gentle
mixing. Beads were then washed 5 times with lysis buffer and eluted with 20 ml of 2x SDS sample buffer. Western blotting was then
performed. Primary antibodies used for IP were as follows: TIAM1 (2 mg/ml; R&D Systems, AF5038) and bTrCP (D13F10; 1:100; Cell
Signaling Technology, 4394).
Western Blotting
Protein extracts were resolved by SDS-PAGE and transferred to nylonmembranes (ImmobilonP) using standard techniques. Primary
antibodies used for Western blotting were as follows: TIAM1 (1:1000; Bethyl, A300-099A), TIAM1 (1:1000; R&D Systems, AF5038),
TAZ (1:200; BD Biosciences, 560235), TAZ (1:500; Sigma-Aldrich, HPA0074), YAP (D8H1X; 1:1000; Cell Signaling Technology,
14074), LMNB1(1:1000; Cell Signaling Technology, 12586), bTrCP (D13F10; 1:1000; Cell Signaling Technology, 4394), bTrCP
(1B1D2; 1:50; Invitrogen, 37-3400), AXIN (C76H11; 1:1000; Cell Signaling Technology, 2087), b-catenin (D10A8; 1:1000; Cell
Signaling Technology, 8480), TEAD4 (1:1000; Abcam, ab58310), panTEAD (D3F7L; 1:1000; Cell Signaling Technology, 13295),
CTGF (L-20; 1:200; SantaCruz Biotechnology, sc14939) and a-tubulin (DM1A; 1:2000; Sigma-Aldrich, T9026).
In Vitro Interaction Assay
Recombinant TIAM1 (1 mg/ml) isolated from insect cell cultures as previously described (Whalley et al., 2015) was incubated with
different concentrations of recombinant TAZ (Abnova H0006901-P01) for 3 hr at 4C and then TIAM1 was immunoprecipitated using
anti-TIAM1-Ab conjugated to Protein G beads for 1 hr at 4Cwith gentlemixing. Beadswere thenwashed 5 timeswith lysis buffer and
eluted with 20 ml of 2x SDS sample buffer. Western blotting was then performed.
Immunofluorescence Microscopy
Cells were grown on glass coverslips and fixed in 3.7% formaldehyde. Post-fixation, cells were washed with PBS, permeabilized for
5 min in 0.5% TritonX-100/PBS and blocked with 5% BSA in 0.1% Triton/PBS for 1 hr before TIAM1 antibody (1:100; R&D Systems,
AF5038) was added.
Transwell Assay
Migration assays were carried out in Boyden chambers using filters (8-mm pore size, Costar). Assay medium (DMEM AQ medium
supplementedwith 20%FBS)was added to the lower compartment, and SW480 andSW620 colon cancer cells, treated as indicated,
were added on top of the insert. After incubation for 24 hr at 37C, filters were fixed. Non-migrated cells were scraped off the upper
side of the filters and the filters were stained with crystal violet. Images were taken under a phase-contrast microscope. The number
of migrated cells was quantified after Crystal Violet elution with 30% (v/v) acetic acid in distilled H2O and 100 ml transferred to a
96-well plate. Absorbance was read at 595 nM.
Proliferation Assay
Cells were transfected 24 hr after seeding and re-transfected on day 3 and 5. Where indicated, treatment with 10 ng/ml Doxycycline
was performed on day 3 and 5. 6 days after the first transfection cell number was estimated by the crystal violet assay. Briefly,
adherent cells were fixed with methanol and stained with 0.5% crystal violet in 20% methanol for 20 min. After gentle rinsing with
water, the retained dye was extracted with 30% (v/v) acetic acid and the absorbance measured at 595 nM.
Duolink PLA
This technique was performed using the Duolink II Red Starter Kit (Sigma). A video summarizing the steps of this technique
can be found online (www.olink.com/products-services/duolink/how-useduolink). Briefly, cells were prepared as above forCancer Cell 31, 621–634.e1–e6, May 8, 2017 e5
immunofluorescence before being incubated overnight at 4C with primary antibodies against TIAM1 [(1:100; Bethyl, A300-099A) or
(1:100; R&DSystems, AF5038)], TAZ [(1:100; BDBiosciences, 560235) or (1:100; Sigma-Aldrich, HPA0074)], YAP (D8H1X; 1:100; Cell
Signaling Technology, 14074) and TEAD4 (1:100; Abcam, ab58310). Slides were then incubated for 1 hr at 37C with a mix of the
MINUS and PLUS PLA probes. Hybridized probes were ligated using the Ligation-Ligase solution for 30 min at 37C and then
amplified utilizing the Amplification-Polymerase solution for 100 min at 37C. Slides were finally mounted using Duolink II Mounting
Medium with DAPI.
Chromatin Immunoprecipitation and Next Generation Sequencing (ChIP-seq)
Chromatin immunoprecipitation was performed using the SimpleChIP Enzymatic Chromatin IP Kit (Magnetic Beads) (Cell Signaling
Technology, 9003) following the instructions of the manufacturer. 10 mg of chromatin was incubated overnight with TAZ antibody
(2 mg/ml; Sigma-Aldrich, HPA0074). The MicroPlex Library Preparation Kit v2 (Diagenode) was used to prepare indexed libraries
from 1 ng of ChIP DNA. The resulting libraries were then size-selected (selecting a 200-800 bp range) by adding 0.55x volume of
AMPure XP beads (Beckman Coulter). To the supernatant, 0.3x the original sample volume of AMPure XP beads were added.
The supernatant was discarded and the beads washed with 70% ethanol before drying and eluting the size-selected library. Library
quality was checked using the Agilent Bioanalyzer. Libraries were quantified by qPCR using the KAPA Library Quantification Kit for
Illumina (Kapa Biosystems Inc.). 1.7 pM pooled libraries were loaded onto the NextSeq 500 and 2x 75 bp sequencing was carried out
using a NextSeq 500/550 High Output v2 kit (Illumina Inc.).
ChIP-seq Analysis
Paired-end sequence (75 bp) was aligned to the human reference genome GRCh37 (Ensembl v75) using bowtie2 (Langmead and
Salzberg, 2012) (version 2.2.1) with default settings. Mapped reads of the same samples across different lanes were merged into
one BAM file. Duplicated reads were removed with Picard tools. Peak calling was performed using MACS2 (Zhang et al., 2008)
(version 2.1.0.20150420) with the call peak function and the parameter ‘‘-p 0.01’’. Peaks were only kept if they had > 15 reads.
We proceeded to identify all overlapping peaks whereby one or more peaks from the WT and KO samples overlapped and extend
the boundaries of these regions to the maximum peak width. Peak overlap was identified using GenomicRanges (Ramirez et al.,
2014) packages in R. We then calculated the RPKM (reads per kilo base per million reads) in the overlapping region and calculated
the fold change. Heatmap visualization of overlapping peaks was performed by deeptools (Lawrence et al., 2013).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistics
The specific statistical tests used are indicated in the figure legends alongside the p values and were carried out using GraphPad
Prism version 6.0. Statistical analysis for the TMA immunohistochemical and survival analysis was performed using IBM SPSS
statistics 23.
DATA AND SOFTWARE AVAILABILITY
Data Resources
The RNA-seq and ChIP-seq data reported in this paper has been deposited to NCBI GEO (http://www.ncbi.nlm.nih.gov/geo) under
the accession number GSE90492.e6 Cancer Cell 31, 621–634.e1–e6, May 8, 2017
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Figure S1, related to Figure 1. Abundance of nuclear TIAM1 impacts on CRC progression. 
(A, B) Pearson Chi-Square test to analyze the correlation between the nuclear intensity of TIAM1 (A) and the 
cytoplasmic intensity of TIAM1 (B) and different Dukes stages of CRC patients. 
(C, D) Mantel-Cox analysis to compare the overall-survival distribution of patients with high and low intensity 
of nuclear (C) or cytoplasmic (D) TIAM1 staining.  
 
 
Table S1, related to Figure 1. Clinico-pathological characteristics of patients and their tumors included in 






Percentage Relationship with overall survival 
Sex    
Male 340 52.3 χ2 = 0.027, p = 0.870 
Female 310 47.7  
Age    
< 70 305 46.9 χ2 = 29.213, p < 0.001 
≥ 70 345 53.1  
Bowel cancer 
screening detected 
   
Yes 52 8 χ2 = 16.381, p < 0.001 
No 598 92  
Tumor site    
Proximal colon 261 40.2 Proximal v distal, χ2 = 8.418, p = 0.004 
Distal colon 245 37.7 Distal v rectal, χ2 = 0.906, p = 0.341 
Rectum 144 22.2 Colon v rectum, χ2 = 0.098, p = 0.754 
Tumor differentiation    
Well/moderate 600 92.3 χ2 = 0.976, p = 0.323 
Poor 50 7.7  
Extra mural venous 
invasion 
   
Present 140 21.5 χ2 = 100.946, p < 0.001 
Absent 510 78.5  
Mismatch repair 
protein status 
   
Defective 96 15.2 χ2 = 2.848, p = 0.091 
Proficient 536 84.8  
Tumor (pT) stage    
pT1 30 4.6 T1 v T2, χ2 = 0.382, p = 0.536 
pT2 114 17.5 T2 v T3, χ2 = 24.739, p < 0.001 
pT3 411 63.2 T3 v T4, χ2 = 30.159, p < 0.001 
pT4 95 14.6  
Lymph node (pN) 
stage 
   
pN0 364 56 N0 v N1, χ2 = 54.071, p < 0.001 
pN1 177 27.2 N1 v N2, χ2 = 17.636, p < 0.001 
pN2 109 16.8  
Dukes stage    
A 120 18.5 A v B, χ2 = 5.059, p = 0.025 
B 244 37.5 B v C, χ2 = 65.510, p < 0.001 
C 286 44  




Figure S2, related to Figure 2. TIAM1 nucleocytoplasmic shuttling is regulated by a bipartite NLS. 
(A) Western blot analyses of cytoplasmic (C) and nuclear (N) fractions from SW480 cells or the CRISPR-
mediated TIAM1 knock-out clones (TIAM1-KO#1, TIAM1-KO#2). α-tubulin and Lamin-B1 were used as 
cytoplasmic and nuclear markers, respectively. Figure representative of three independent experiments. 
(B) Representative confocal images from three independent experiments of endogenous TIAM1 in SW480 cells 
or the CRISPR-mediated TIAM1 knock-out clones. Scale bars, 10 μm. 
(C) Sequencing results for the TIAM1 locus from genomic DNA isolated from SW480 cells or the CRISPR-
mediated TIAM1 knock-out clones. 
(D) In silico analysis of TIAM1 sequence for the prediction of putative NLSs. 
(E) Alignment of TIAM1 protein sequence from different species to determine the conservation and homology 
of potential TIAM1 NLSs among various species. 
(F) Representative confocal images of DLD1 cells transiently transfected with GFP-tagged FL-TIAM1 and 
TIAM1-ΔNLS2 constructs. Graph shows quantitation from three independent experiments (n = 50 cells per 




Figure S3, related to Figure 3. TIAM1 suppresses a TAZ/YAP transcriptional program. 
(A) Western blot analyses of endogenous proteins in SW620 cells transfected with control siRNA (siNT) or 
TIAM1#1 siRNA as indicated. 
(B) Principal component analysis of RNA-seq expression data from all biological replicates of siNT, 
siTIAM1#1 and siTAZ/YAP transfected SW620 cells (n = 3). 
(C) qPCR for TIAM1 normalized to ACTB expression in SW480 and SW620 cells transfected with TIAM1#1 or 
TIAM1#2 siRNA.  
(D) qPCR for TAZ/YAP target genes AMOTL2, ANKRD1, AXL, CTGF and CYR61 normalized to ACTB 
expression in SW620 and SW480 cells transfected with TIAM1#2 siRNA. 
(E) Western blot analyses of endogenous proteins in SW620 cells transfected with YAP or TAZ siRNAs or 
siNT as indicated. 
Data are relative to negative control siRNA and are presented as mean ± SEM (with siNT set as 1) (unpaired t-
test, *p < 0.05, **p < 0.01, ***p < 0.001). 
 
 
Table S2, related to Figure 3. TIAM1 differentially expressed genes. Provided as an Excel file. 






Figure S4, related to Figure 4. TIAM1 regulates TAZ stability and nuclear translocation. 
(A) qPCR for TIAM1 normalized to ACTB expression in confluent HEK293 cells transfected with TIAM1#1 
siRNA.  
(B) Western blot analyses of cytoplasmic (C) and nuclear (N) fractions from confluent HEK293 cells transfected 
with TIAM1#2 siRNA. Graph shows mean TAZ and YAP levels normalized to cytoplasmic (α-tubulin) or 
nuclear (Lamin-B1) markers and then to negative control siRNA (siNT) from three independent replicates. 
(C) qPCR for TAZ normalized to ACTB expression in confluent HEK293 cells transfected with TIAM1#1 
siRNA.  
(D) Luciferase assay using 8xGTIIC-Lux or control reporter indicating TAZ/YAP-dependent transcriptional 
activity in confluent HEK293 cells transfected with TIAM1#1 siRNA, either alone or with two different 
TAZ/YAP siRNAs as indicated. Data are normalized to a co-transfected Renilla reporter and to negative control 
siRNA (siNT).  
(E) Western blot analyses of endogenous proteins in HEK293 or HaCaT cells transfected with TIAM1#1 
siRNA, either alone or with two different YAP or TAZ siRNAs (or pairs thereof) as indicated. Figure 
representative of three independent experiments. 
(F) qPCR for TAZ/YAP target genes CTGF and CYR61 normalized to ACTB expression in confluent HEK293 
and HaCaT cells transfected with TIAM1#1 siRNA, either alone or with two different YAP or TAZ siRNAs as 
indicated. 
(G) qPCR for TAZ/YAP target genes CTGF and CYR61 normalized to ACTB expression in confluent HEK293 
cells transfected with TIAM1#2 siRNA, either alone or with two different YAP or TAZ siRNAs as indicated. 
Data are normalized to negative control siRNA (siNT) and are presented as mean ± SEM (with siNT set as 1) 




Figure S5, related to Figure 5. TIAM1 is regulated by the canonical WNT pathway. 
(A, B) qPCR for APC (A) and TIAM1 (B) normalized to ACTB expression in confluent HEK293 cells 
transfected with APC siRNA. Data are normalized to negative control siRNA (siNT) and are presented as mean 
± SEM (with siNT set as 1) (unpaired t-test, **p < 0.01, ***p < 0.001). 
(C) Representative confocal images of TIAM1 localization in confluent HEK293 cells transfected with control 




Figure S6, related to Figure 6. Nuclear TIAM1 antagonizes TAZ transcriptional activity. 
(A, B) Western blot analyses of endogenous TAZ co-immunoprecipitating with endogenous TIAM1 from 
cytoplasmic (C) and nuclear (N) fractions of SW620 (A) or SW480 (B) cells. IgG was used as a control 
antibody for immunoprecipitation. α-tubulin and Lamin-B1 were used as cytoplasmic and nuclear markers, 
respectively. Figure representative of three independent experiments. 
(C) Western blot analyses of endogenous proteins in SW620 or DLD1 cells transfected with TIAM1#1, YAP#1 
and TAZ#2 siRNAs or all three siRNAs as indicated. Figure representative of three independent experiments. 
(D) Western blot analyses of endogenous YAP co-immunoprecipitating with endogenous TEAD from nuclear 
fractions of parental SW480 cells or the CRISPR-mediated TIAM1 knock-out clones. IgG was used as a control 
antibody for immunoprecipitation. Graph shows mean levels of immunoprecipitated YAP normalized to levels 
of immunoprecipitated TEAD from three independent replicates. 
(E) Representative confocal images of YAP/TEAD interaction in parental SW480 cells or the CRISPR-mediated 
TIAM1 knock-out clones detected by DUOLINK assay. Graph shows quantitation from three independent 
experiments Scale bars, 10 μm. 
(F) Venn diagram showing overlap of TAZ-associated genomic DNA peaks in parental and TIAM1-KO#1 
SW480 cells as determined by ChIP-seq analysis. 
Data shown in graphs are presented as mean ± SEM with parental set as 1 (unpaired t-test, *p < 0.05). 
 
 
Figure S7, related to Figure 7. Effect of TIAM1 on cell proliferation. 
(A) Average number of DLD1, SW480 and SW620 cells 6 days following transfection with siRNA for TIAM1 
or TAZ/YAP either alone or in combination, as indicated. Results were normalized to negative control siRNA 
(siNT). 
(B) Representative confocal images of HEK293 cells transiently transfected with HA-tagged FL-TIAM1 or 
NLS-TIAM1 constructs stained for the HA tag and counterstained with DAPI. Scale bars, 10 μm. 
(C) Representative western blots from three independent experiments for DLD1 and SW620 cells transfected 
with TIAM1#1 siRNA inducibly expressing either FL-TIAM1 or NLS-TIAM1 resistant to siTIAM1#1 
following addition of 10 ng/ml Doxycycline (Plus Dox). ACTIN is used as a loading control. Graphs show 
changes in cell number 6 days following siRNA transfection and Doxycycline addition.  
(D) Representative western blots from three independent experiments of parental and SW480 CRISPR-mediated 
TIAM1 knock-out cells (TIAM1-KO#1 clone) inducibly expressing either FL-TIAM1 or NLS-TIAM1 
following addition of 10 ng/ml Doxycycline (Plus Dox). ACTIN is used as a loading control. Graph shows 
changes in cell number 6 days following Doxycycline addition. 
Data are presented as mean ± SEM with siNT (A, C) or parental (D) set as 100 (unpaired t-test, *p < 0.05, **p < 
0.01, ***p < 0.001, ns: not significant). 
  
Table S4, related to Key Resources Table. List of oligonucleotides used in this study. 
Oligonucleotides 
qPCR Primers: ACTB-Fwd: 5’-
ATTGGCAATGAGCGGTTC-3’ and Rev: 5’-
GGATGCCACAGGACTCCAT-3’ 
This study N/A 
qPCR Primers: APC-Fwd: 5’-
GACCGTTTCCTCAGGTGCTA-3’ and Rev: 5’-
AATGGGACAGTCCTCAATTCTC-3’   
This study N/A 
qPCR Primers: CTGF-Fwd: 5’-
CCTGCAGGCTAGAGAAGCAG-3’ and Rev: 5’-
TGGAGATTTTGGGAGTACGG-3’ 
This study N/A 
qPCR Primers: CYR61-Fwd: 5’-
CCAGTGTACAGCAGCCTGAA-3’ and Rev: 5’-
GGCCGGTATTTCTTCACACTC-3’ 
This study N/A 
qPCR Primers: TIAM1-Fwd: 5’-
CCATGAGCAGGGCAGTGT-3’ and Rev: 5’-
CGGAGACGGCATCAGAAT-3’ 
This study N/A 
qPCR Primers: AMOTL2 ThermoFisher Scientific Cat# Hs01048101_m1 
qPCR Primers: ANKRD1 ThermoFisher Scientific Cat# Hs00173317_m1 
qPCR Primers: AXL ThermoFisher Scientific Cat# Hs01064444_m1 
qPCR Primers: WWTR1 (TAZ) ThermoFisher Scientific Cat# Hs00210007_m1 
Cloning primer: NLS-TIAM1: 5’-
ATGGGTCCTCCAAAAAAGAAGAGAAAGGTA-3’ 
This study N/A 
Cloning primer: TIAM1ΔNLS2-Fwd:  5’- 
ACCATCAACCAGGTGTTTGGA-3’ and Rev: 5’-  
AGGCGTACTCAGGCCATGTCC-3’ 
This study N/A 
Cloning primer: TIAM1-m1-Fwd: 5’-  
CCAGAGAGAAGAAAACCTGCTCGCTGCCGCGCTT
GCAGACCTGGACATGGCC-3’ and Rev: 5’- 
GGCCATGTCCAGGTCTGCAAGCGCGGCAGCGAGC
AGGTTTTCTTCTCTCTGG-3’ 
This study N/A 
Cloning primer: TIAM1-m2-Fwd: 5’- 
GTTGATGGTTGGGCGTCCCTGCGCCGCTGCGGAG
GTAGTGTCTAGGCCCCAG-3’ and Rev: 5’- 
CTGGGGCCTAGACACTACCTCCGCAGCGGCGCAG
GGACGCCCAACCATCAAC-3’ 
This study N/A 
sgRNA sequence: TIAM1-KO: 5’- 
GCTCATCGCTGTGCGCCGAGC-3  
Shalem et al., 2014 N/A 
siRNA sequence for APC ThermoFisher Scientific Cat# s1433 
siRNA#1 sequence for YAP1 ThermoFisher Scientific Cat# s20366 
siRNA#2 sequence for YAP1 ThermoFisher Scientific Cat# s20367 
siRNA#1 sequence for WWTR1 (TAZ) ThermoFisher Scientific Cat# s24789 
siRNA#2 sequence for WWTR1 (TAZ) ThermoFisher Scientific Cat# s24787 
siRNA#1 sequence for TIAM1: 5’-
GAGGUUGCAGAUCUGAGCA-3’ 
Vaughan et al., 2015 N/A 
siRNA#2 sequence for TIAM1: 5’-
AGAGCGCACCUACGUGAAA-3 
Vaughan et al., 2015 N/A 
siRNA sequence for NT ThermoFisher Scientific Negative Control #1 
 
 
 
